StockTipsArenaBeta

BUY Piramal Pharma Limited — IDBI Capital

BUYPiramal Pharma Limited
Piramal Pharma share price target & all analyst calls

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))27 Aug 2026via IDBI Capital Research Calls Telegram

Entry₹215Stated
Target₹230
Total upside +6.98% (call closed)
Stop loss₹208-3.26% risk
Exit₹2308 Sept 2026, 11:15 am
Target hit+6.98%0.00%upside left
Follow IDBI Capital for new calls(25% target hit, 371 closed calls)Get alertsWatch PPLPHARMA for new buy/sell callsGet alertsSee 105 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 8 Sept 2026
9 supporting4 neutral2 opposing
Supports the BUY call (9)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·7 Sept · yesterday

Piramal Pharma: अमेरिकी टैरिफ के खतरे के बीच कंपनी की नई स्ट्रैटेजी, मुनाफे में दमदार उछाल

NewsGoogle News·5 Sept · 3d ago

(opens in new tab)

Piramal Pharma CDMO Strategy Helps Clients Navigate US Tariff Risks

NewsGoogle News·5 Sept · 3d ago

(opens in new tab)

Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations

NewsGoogle News·26 Aug · 2w ago

(opens in new tab)

2 advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·26 Aug · 2w ago

Neutral / worth noting (4)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 2w ago

(opens in new tab)

US envoy Sergio Gor meets Piramal Group Chairman Ajay Piramal, discusses expansion plans in US

NewsGoogle News·27 Aug · 2w ago

(opens in new tab)

Piramal Pharma emphasises sustainability in FY 2025-26 report

NewsGoogle News·24 Aug · 2w ago

(opens in new tab)

Piramal Pharma Block Deal: Seller likely to offload 6% stake for around ₹1,750 crore

NewsCnbc-Tv18·13 Aug · 4w ago

(opens in new tab)
Weighs against the BUY call (2)

Piramal Pharma reports 22.6% drop in Scope 1 & 2 emissions for FY26

NewsGoogle News·24 Aug · 2w ago

(opens in new tab)

Piramal Pharma block deal likely cancelled; stock falls 3%

NewsCnbc-Tv18·14 Aug · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Piramal Pharma

All analyst calls on Piramal Pharma

More from IDBI Capital

Every call and its outcome